Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March
Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March
Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% from the February 28th total of 7,300 shares. Based on an average trading volume of 19,300 shares, the short-interest ratio is currently 0.5 days.
奇魯達公司（NASDAQ：CELUW-獲取評級）在 3 月份短期興趣大幅增加。截至 3 月 15 日，短期利息總額為 8,700 股，較 2 月 28 日的 7,300 股股份增加 19.2%。根據 19,300 股的平均交易量計算，短息比率目前為 0.5 天。
Celularity Price Performance
卓越性價格表現
Shares of NASDAQ CELUW remained flat at $0.06 during midday trading on Friday. 56,760 shares of the stock were exchanged, compared to its average volume of 21,241. The firm's fifty day moving average is $0.08. Celularity has a fifty-two week low of $0.05 and a fifty-two week high of $1.99.
納斯達克 CELUW 的股票在周五中午交易期間保持平穩 0.06 美元。與其平均交易量為 21,241 股相比，該股票的交易量為 56,760 股。該公司的五十天移動平均線為 0.08 美元。天然有五十二周低點 0.05 美元和五十二周的高點 1.99 美元。
About Celularity
關於卓越
(Get Rating)
(取得評分)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc 是臨床階段的生物技術公司，開發現成的胎盤衍生異基因細胞療法，用於治療癌症，免疫和傳染病。它通過三個部分進行操作：細胞治療，退行性疾病和生物班王。該公司的主要治療方案包括 CYCART-19，胎盤衍生的 CAR-T 療法，該療法正在治療 B 細胞惡性腫瘤的 I 期臨床試驗中；CYNK-001，胎盤衍生的未修飾天然殺傷劑（NK）細胞，該細胞處於治療急性髓細胞白血病的 I 期臨床試驗中，以及用於治療急性髓細胞白血病的 I/IIA 期臨床試驗中，用於膠質瘤和 COVID-19 多形瘤治療試驗; CYNK-101 是一種異體轉基因 NK 細胞，正處於治療 HER2+ 胃癌和胃食管癌的 I 期臨床試驗中；APPL-001，胎盤-衍生的間充質樣附著劑基質細胞，處於治療克羅恩氏病的臨床前階段；和 PDA-002，胎盤衍生的間葉類粘附劑基質細胞，處於臨床前階段，用於治療面部異位素的肌肉營養不良。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 免費獲取有關天然性研究報告的副本
- 市場節拍週的回顧 — 3 月 27 日 — 3/31
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze 公司準備火箭更高嗎？
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日奇魯特的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Celularity 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。